miR-647在结肠癌细胞中的表达及临床意义  

The expression and clinical significance of miR-647 in colon cancer cells

作　　者：刘少卿[1] 何晨翔 李卫萍[2] 屈丁丁 张健[3] 李世森[1] 吴国生[1] 郑建勇[1] 

机构地区：[1]第四军医大学西京消化病医院消化外科,陕西西安710032 [2]陕西中医药大学,陕西咸阳712046 [3]第四军医大学基础部生物化学与分子生物学教研室,陕西西安710032

出　　处：《现代肿瘤医学》2017年第4期507-511,共5页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(编号:81572816)

摘　　要：目的:分析miR-647在结肠癌组织及细胞系中的表达情况,探讨其对结肠癌细胞增殖、迁移能力的影响及其可能的作用机理。方法:利用Real-time quantitative Polymerase Chain Reaction(q PCR)技术检测17例结肠癌患者癌及癌旁组织中miR-647的表达;利用q PCR技术检测正常人肠上皮细胞HIEC及结肠癌细胞HT-29中miR-647的表达;将miR-647 antagomir及对照分别转染至结肠癌细胞中,应用MTT实验检测细胞增殖,体外划痕实验检测细胞迁移能力,评价转染miR-647抑制剂对结肠癌细胞增殖能力和迁移能力的影响。结果:q PCR结果显示,与癌旁组织相比,miR-647在结肠癌肿瘤组织中表达明显升高;与正常人肠上皮细胞相比,人结肠癌细胞系HT-29中miR-647表达明显升高;MTT结果显示miR-647抑制剂可以显著抑制SW480和SW620细胞的增殖能力和细胞迁移能力。结论:miR-647通过促进结肠癌细胞的增殖和迁移能力,参与结肠癌的发生发展进程。Objective： To analyze the expression of miR- 647 in colon cancer tissues and colon cancer cell lines,explore the influences of miR- 647 on cell proliferation and migration,and discuss the possible mechanism. Methods： Detecting the expression of miR- 647 in 17 pairs of colon cancer tissues and adjacent tissues by Real- time quantitative Polymerase Chain Reaction（ q PCR）. Analyzing the expression of miR- 647 in HIEC and HT-29 by qPCR. Transfecting miR-647 antagomir and negative control into colon cancer cells by using the LipofectaminTM RNAi MAX,and then testing the cell proliferation and migration by MTT and wound healing assay respectively. Results： q PCR showed that miR-647 was significantly increased in tumor tissue of patients with colon cancer compared with the adjacent tissues. And miR- 647 was also notably increased in colon cancer cell line（HT-29） compared with the HIEC. MTT and wound healing assay results showed that miR- 647 antagomir significantly inhibited the proliferation and migration of SW480 and SW620 cells. Conclusion： miR- 647 participated in the process of colon cancer development by promoting the proliferation and migration abilities of colon cancer cell lines.

关 键 词：MIRNA 细胞增殖 迁移 结肠癌 

分 类 号：R735.35[医药卫生—肿瘤]